Biomedical Pioneering Innovation Center, Department of General Surgery, School of Life Sciences, Third Hospital, Peking University, Beijing, 100871, People's Republic of China.
Beijing Advanced Innovation Center for Genomics & Key Laboratory of Assisted Reproduction, Ministry of Education, Beijing, 100871, People's Republic of China.
Genome Med. 2022 Aug 16;14(1):93. doi: 10.1186/s13073-022-01093-z.
Colorectal cancer (CRC) ranks as the second-leading cause of cancer-related death worldwide with metastases being the main cause of cancer-related death. Here, we investigated the genomic and transcriptomic alterations in matching adjacent normal tissues, primary tumors, and metastatic tumors of CRC patients.
We performed whole genome sequencing (WGS), multi-region whole exome sequencing (WES), simultaneous single-cell RNA-Seq, and single-cell targeted cDNA Sanger sequencing on matching adjacent normal tissues, primary tumors, and metastatic tumors from 12 metastatic colorectal cancer patients (n=84 for genomes, n=81 for exomes, n=9120 for single cells). Patient-derived tumor organoids were used to estimate the anti-tumor effects of a PPAR inhibitor, and self-renewal and differentiation ability of stem cell-like tumor cells.
We found that the PPAR signaling pathway was prevalently and aberrantly activated in CRC tumors. Blocking of PPAR pathway both suppressed the growth and promoted the apoptosis of CRC organoids in vitro, indicating that aberrant activation of the PPAR signaling pathway plays a critical role in CRC tumorigenesis. Using matched samples from the same patient, distinct origins of the metastasized tumors between lymph node and liver were revealed, which was further verified by both copy number variation and mitochondrial mutation profiles at single-cell resolution. By combining single-cell RNA-Seq and single-cell point mutation identification by targeted cDNA Sanger sequencing, we revealed important phenotypic differences between cancer cells with and without critical point mutations (KRAS and TP53) in the same patient in vivo at single-cell resolution.
Our data provides deep insights into how driver mutations interfere with the transcriptomic state of cancer cells in vivo at a single-cell resolution. Our findings offer novel knowledge on metastatic mechanisms as well as potential markers and therapeutic targets for CRC diagnosis and therapy. The high-precision single-cell RNA-seq dataset of matched adjacent normal tissues, primary tumors, and metastases from CRCs may serve as a rich resource for further studies.
结直肠癌(CRC)是全球癌症相关死亡的第二大主要原因,转移是癌症相关死亡的主要原因。在这里,我们研究了 CRC 患者匹配的相邻正常组织、原发肿瘤和转移瘤中的基因组和转录组改变。
我们对 12 例转移性结直肠癌患者的匹配相邻正常组织、原发肿瘤和转移瘤进行了全基因组测序(WGS)、多区域全外显子组测序(WES)、单细胞 RNA-Seq 同步和单细胞靶向 cDNA Sanger 测序(基因组 84 例,外显子组 81 例,单细胞 9120 例)。患者来源的肿瘤类器官用于估计 PPAR 抑制剂的抗肿瘤作用以及干细胞样肿瘤细胞的自我更新和分化能力。
我们发现 PPAR 信号通路在 CRC 肿瘤中普遍异常激活。体外阻断 PPAR 通路不仅抑制了 CRC 类器官的生长,还促进了其凋亡,表明异常激活的 PPAR 信号通路在 CRC 肿瘤发生中起着关键作用。使用来自同一患者的匹配样本,揭示了淋巴结和肝脏转移瘤之间不同的起源,这在单细胞分辨率下通过拷贝数变异和线粒体突变谱进一步得到证实。通过结合单细胞 RNA-Seq 和靶向 cDNA Sanger 测序的单细胞点突变鉴定,我们在单细胞分辨率下揭示了具有关键点突变(KRAS 和 TP53)的癌症细胞与没有关键点突变的癌症细胞之间的重要表型差异。
我们的数据深入了解了驱动突变如何在体内以单细胞分辨率干扰癌症细胞的转录组状态。我们的发现为转移性机制提供了新的认识,为 CRC 的诊断和治疗提供了潜在的标志物和治疗靶点。CRC 匹配的相邻正常组织、原发肿瘤和转移瘤的高精度单细胞 RNA-seq 数据集可为进一步研究提供丰富的资源。